Figure 4

Kaplan-Meier analysis of the survival of patients with or without MYCN amplification and 12q24 gain. The prognosis of patients with 12q24 gain was intermediate when compared to those with MYCN amplification or patients with no amplification/gain of either locus. Numbers in parenthesis refer to the number of patients included in each category. Crosses indicate the lengths of follow-up for those patients whose follow-up was terminated before the last time point.